A selection of recently published medical articles authored by Penn experts are available below for reference and information.

Cardiovascular Risk Assessment

The evolution and refinement of traditional risk factors for cardiovascular disease. deGoma EM, Knowles JW, Angeli F, Budoff MJ, Rader DJ. Cardiol Rev. 2012 May;20(3):118-29.

Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Jacoby DS, Mohler III ER, Rader DJ. Curr Atheroscler Rep. 2004 Jan;6(1):20-6.


Demystifying triglycerides: a practical approach for the clinician. Dunbar RL, Rader DJ. Cleve Clin J Med. 2005 Aug;72(8):661-6.

Inflammation and Cardiometabolic Disease

Underdiagnosis and undertreatment of risk factors for heart disease in psoriasis:Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, Hsu MC, Yeilding N, Rader DJ, Mehta NN. J Am Acad Dermatol. 2011 Oct;21[Epub ahead of print]

Psoriasis increases cardiovascular events. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Eur Heart J. 2010 Apr;31(8):1000-6. Epub 2009 Dec 27.

Psoriasis increases cardiovascular mortality. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Eur Heart J. 2010 Apr;31(8):1000-6. Epub 2009 Dec 27.

Psoriasis increases systemic inflammation by FDG PET/CT. Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM. Arch Dermatol. 2011 Sep;147(8):1031-9. Epub May 16.

Inflammation in the fat tissue can lead to systemic insulin resistance. Mehta NN, McGillicuddy FC, Anderson PD, Hinkle CC, Shah R, Pruscino L, Tabita-Martinez J, Sellers KF, Rickels MR, Reilly MP. 2010 Jan;59(1):172-81. Epub 2009 Sep 30.

Understanding how fat tissue relates to insulin resistance and vascular disease. Shah A, Mehta N, Reilly MP. 2008 Nov-Dec;32(6):638-44.

Metabolic syndrome (pre-diabetes) is increased in patients with psoriasis. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. 2011 Nov 24. doi: 10.1038/jid.2011.365.[Epub ahead of print]


Extremely elevated lipoprotein(a), combined hyperlipidemia, and premature atherosclerosis. deGoma EM, Wheeler MT, Marcovina SM, Ashley EA. J Clin Lipidol. 2010 Nov-Dec;4(6):543-7.

Personalized Medicine

Personalized vascular medicine: Individualizing drug therapy. deGoma EM, Rivera G, Lilly SM, Usman MH, Mohler ER 3rd. Vasc Med. 2011 Oct;16(5):391-404.

Therapies in Development

Novel HDL-directed pharmacotherapeutic strategies. deGoma EM, Rader DJ. Nat Rev Cardiol. 2011 May;8(5):266-77.

Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Chauffe RJ, Wilensky RL, Mohler ER 3rd. Curr Atheroscler Rep. 2010 Jan;12(1):43-7.

Women's Health

The underappreciated impact of heart disease. deGoma EM, Karlsberg RP, Judelson DR, Budoff MJ. Womens Health Issues. 2010 Sep;20(5):299-303.

Share This Page: